**Tables**

## **Table 1: Study characteristics of the 37 selected studies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author** | **Date of Publication** | **Country** | **Study Design** | **Number Ped Patients** | **JBI scaled score** |
| Korkmaz MF et al.11 | Jul-20 | Turkey | Cross-sectional | 81 | 8.5 |
| Liu YJ et al. 12 | Jun-20 | China | Cross-sectional | 53 | 8.1 |
| Zhang C et al. 13 | Jun-20 | China | Cross-sectional | 34 | 8.9 |
| Lan L et al. 14 | Jun-20 | China | Case series | 4 | 8.8 |
| Sun D et al.15 | Jun-20 | China | Cross-sectional | 36 | 8.8 |
| Toubiana J et al.16 | Jun-20 | France | Cross-sectional | 21 | 9.2 |
| Wu H et al. 17 | Jun-20 | China | Case series | 148 | 8.4 |
| Harman K et al. 18 | Jun-20 | UK | Case series | 12 | 8.3 |
| Dallan C et al. 19 | May-20 | Switzerland | Case series | 3 | 8.0 |
| Wu HP et al. 20 | May-20 | China | Cross-sectional | 23 | 8.1 |
| Chen J et al.21 | May-20 | China | Case series | 20 | 7.5 |
| Li Y et al. 22 | May-20 | China | Case series | 8 | 8.1 |
| Riphagen S et al. 23 | May-20 | UK | Case series | 2 | 6.4 |
| Zhong Z et al. 24 | May-20 | China | Case series | 9 | 8.0 |
| Lu Y et al. 25 | May-20 | China | Cross-sectional | 110 | 8.8 |
| Ma H et al. 26 | May-20 | China | Cross-sectional | 50 | 8.9 |
| Song W et al. 27 | May-20 | China | Case series | 16 | 8.0 |
| Nathan N et al. 28 | May-20 | France | Case series | 5 | 6.8 |
| Tan YP et al. 29 | Apr-20 | China | Case series | 10 | 9.3 |
| Jiang S et al. 30 | Apr-20 | China | Case series | 2 | 7.0 |
| Shen Q et al. 31 | Apr-20 | China | Case series | 9 | 8.5 |
| Liu W et al. 32 | Mar-20 | China | Case Series | 6 | 8.8 |
| Su et al. 33 | Mar-20 | China | Cross-sectional | 9 | 7.3 |
| Xu et al. 34 | Apr-20 | China | Case-series | 10 | 7.9 |
| Zhang T. et al. 35 | Mar-20 | China | Case series | 3 | 7.9 |
| Lu X et al. 36 | Mar-20 | China | Cross-sectional | 171 | 5.8 |
| Liu H et al. 37 | Mar-20 | China | Cross-sectional | 4 | 8.8 |
| Xia W et al. 38 | Mar-20 | China | Cross-sectional | 20 | 7.6 |
| Wang D et al. 39 | Mar-20 | China | Cross-sectional | 31 | 8.3 |
| Tan X et al.40 | Apr-20 | China | Cross-sectional | 13 | 5.4 |
| Xing YH et al. 41 | Apr-20 | China | Case series | 3 | 8.0 |
| Qiu H et al. 42 | Mar-20 | China | Cross-sectional | 36 | 8.7 |
| Sun D et al.43 | Mar-20 | China | Case series | 8 | 8.5 |
| Ji LN et al. 44 | Mar-20 | China | Case series | 2 | 7.6 |
| Li W et al. 45 | Mar-20 | China | Case series | 5 | 8.5 |
| Hu Z et al. 46 | Mar-20 | China | Case series | 6 | 7.4 |
| Cai J et al. 47 | Mar-20 | China | Case series | 10 | 8.8 |

## **Table 2: Results of meta-analysis: Demographics, co-morbidities, and clinical presentation**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Item** | **No. of studies** | **Proportion %** | **95% CI** | **n** | **Q** | **I2** | **T2** | **P-value** | **Egger’s test P** |
| **Demographic Characteristics** | | | | | | | | |  |
| Age (mean in years) | 37 | 6.63 (0.90) | 4.9 – 8.4 | 36 | 6854.1 | 99.5 | 27.5 | < 0.001 | 0.00001 |
| Male | 37 | 52.2 | 47.7 – 56.6 | 36 | 50.5 | 28.7 | 0.1 | 0.055 | 0.9776 |
| Female | 37 | 47.8 | - | - | - | - | - | - | - |
| **Co-Morbidities** |  |  |  |  |  |  |  |  |  |
| All co-morbidities | 18 | 14.5 | 8.3 – 24.2 | 17 | 51.4 | 66.9 | 1.0 | < 0.001 | 0.7267 |
| Congenital heart disease | 10 | 5 | 2.5 – 9.8 | 9 | 7.77 | 0 | 0 | 0.557 | 0.3842 |
| Obesity | 15 | 4.9 | 1.9 – 11.8 | 14 | 24.2 | 42.14 | 1.53 | 0.043 | 0.0226 |
| Prematurity | 7 | 4 | 1.5 – 10.4 | 6 | 5.59 | 0 | 0 | 0.471 | 0.6796 |
| Neurological\* | 15 | 3.7 | 2.0 – 6.6 | 14 | 7.25 | 0 | 0 | 0.925 | 0.446 |
| Cancer | 17 | 3.6 | 1.9 – 6.4 | 16 | 11.6 | 0 | 0 | 0.773 | 0.768 |
| Asthma | 15 | 3.2 | 1.7 – 6.2 | 14 | 11.43 | 0 | 0 | 0.652 | 0.6694 |
| Diabetes | 14 | 2.8 | 1.4 – 5.6 | 13 | 7.31 | 0 | 0 | 0.886 | 0.074 |
| **Clinical Presentation** | | | | | | | | |  |
| Asymptomatic | 34 | 23.8 | 17.6-31.2 | 33 | 91.4 | 63.9 | 0.5 | <0.001 | 0.9019 |
| Fever | 37 | 52.5 | 45.7 – 59.1 | 36 | 88.7 | 59.4 | 59.4 | 0.227 | 0.3402 |
| Cough | 34 | 47.6 | 41.2 – 54.0 | 33 | 73.2 | 54.9 | 0.2 | < 0.001 | 0.4640 |
| Expectoration | 11 | 19.5 | 11.7 – 30.7 | 10 | 17.5 | 43.0 | 0.4 | 0.378 | 0.063 |
| Headache | 14 | 10.5 | 5.4 – 19.3 | 13 | 37.7 | 65.5 | 1.0 | < 0.001 | 0.5224 |
| Dyspnea | 19 | 12.9 | 6.6 – 23.7 | 18 | 107.0 | 83.2 | 1.6 | < 0.001 | 0.01566 |
| Sore Throat/ Pharyngitis | 22 | 16.0 | 8.5 – 27.9 | 21 | 98.0 | 78.6 | 1.8 | < 0.001 | 0.01030 |
| Rhinorrhea | 20 | 15.1 | 9.8 – 22.6 | 19 | 52.0 | 63.5 | 0.7 | < 0.001 | 0.4394 |
| Nasal Congestion | 9 | 10.3 | 4.2 – 23.2 | 8 | 19.5 | 59.0 | 1.1 | 0.012 | 0.6705 |
| Nausea / vomiting | 20 | 12.9 | 7.5 – 21.3 | 19 | 44.5 | 57.3 | 0.9 | 0.001 | 0.5129 |
| Abdominal pain | 13 | 8.3 | 4.0 – 16.4 | 12 | 17.7 | 32.4 | 0.6 | 0.124 | 0.6535 |
| Diarrhea | 22 | 13.3 | 9.3 – 18.6 | 21 | 30.8 | 31.9 | 0.1 | 0.241 | 0.8769 |
| Rash | 7 | 18.7 | 3.8 – 57.0 | 6 | 26.0 | 77.0 | 4.1 | < 0.001 | 0.0136 |
| Myalgia | 9 | 4.1 | 2.1 – 7.9 | 8 | 8.4 | 4.3 | 0.1 | 0.400 | 0.7556 |
| Fatigue | 15 | 6.1 | 4.3 – 8.6 | 14 | 10.8 | 0.0 | 0.0 | 0.702 | 0.2245 |

n degree of freedom, Q Cochran's Q statistic for heterogeneity, I2 Index for the degree of heterogeneity, T2 Tau-squared measure of heterogeneity.

\* Neurological– Febrile seizures, Epilepsy, Cerebral palsy

**Table 3: Results of meta-analysis: Laboratory and radiological investigations**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Items** | **No. of studies** | **Proportion (%)** | **95% CI** | **n** | **Q** | **I2** | **T2** | **P-value** | **Egger’s test P** |
| **Laboratory Investigations** | | | | | | | | | |
| Leukocytosis | 32 | 12.8 | 8.9 – 18.2 | 31 | 48.1 | 35.6 | 0.4 | 0.026 | 0.8715 |
| Leukopenia | 35 | 13.9 | 10.1 – 18.8 | 34 | 78.4 | 56.7 | 0.5 | < 0.001 | 0.0219 |
| Lymphocytosis | 29 | 15.3 | 9.9 – 23.0 | 28 | 67.5 | 58.5 | 0.8 | < 0.001 | 0.0022 |
| Lymphopenia | 33 | 12.7 | 7.6 – 20.4 | 32 | 118.7 | 73.0 | 1.7 | < 0.001 | 0.5502 |
| Neutrophilia | 21 | 9.3 | 6.8 – 12.6 | 20 | 17.7 | 0.0 | 0.0 | < 0.001 | 0.5871 |
| Neutropenia | 19 | 16.6 | 10.2 – 25.8 | 18 | 34.8 | 48.2 | 0.6 | 0.010 | 0.8010 |
| Elevated CRP | 37 | 22.6 | 17.2 – 29.0 | 36 | 93.0 | 61.3 | 0.4 | < 0.001 | 0.6486 |
| Elevated ESR | 13 | 14.2 | 8.5 – 22.6 | 12 | 20.4 | 41.2 | 0.4 | 0.060 | 0.3032 |
| Elevated procalcitonin | 27 | 31.8 | 22.3 – 43.1 | 26 | 128.7 | 79.8 | 0.8 | < 0.001 | 0.0179 |
| Elevated IL-6 | 9 | 5.2 | 1.5 – 16.4 | 8 | 29.7 | 73.1 | 2.4 | < 0.001 | 0.4438 |
| Elevated IL-10 | 6 | 9.9 | 6.5 – 14.9 | 5 | 6.6 | 23.9 | 0.1 | < 0.001 | 0.0405 |
| Abnormal LFTs | 27 | 21.3 | 14.6 – 30.0 | 26 | 104.6 | 75.2 | 0.8 | < 0.001 | 0.9881 |
| Elevated Creatinine | 13 | 7.0 | 2.3 – 19.7 | 12 | 43.1 | 72.1 | 3.1 | < 0.001 | 0.0007 |
| Elevated LDH | 18 | 27.6 | 18.1 – 39.6 | 17 | 71.6 | 76.3 | 0.9 | < 0.001 | 0.9779 |
| Elevated D-dimer | 24 | 16.2 | 10.9 – 23.4 | 23 | 58.0 | 60.4 | 0.6 | < 0.001 | 0.3482 |
| Elevated CK | 17 | 17.0 | 10.1 – 27,3 | 16 | 67.1 | 76.1 | 0.9 | < 0.001 | 0.0029 |
| Elevated CK-MB | 11 | 21.1 | 11.9 – 34.6 | 10 | 46.3 | 78.4 | 0.9 | < 0.001 | 0.0288 |
| Elevated troponin | 7 | 23.0 | 3.6 – 70.0 | 6 | 45.8 | 86.9 | 6.3 | < 0.001 | 0.7442 |
| Total co-infections | 21 | 22.4 | 15.0 – 31.9 | 20 | 57.6 | 65.2 | 0.6 | < 0.001 | 0.0419 |
| Viral co-infections | 17 | 8.5 | 3.7 – 18.2 | 16 | 47.7 | 66.5 | 1.9 | <0.001 | 0.0019 |
| Influenza A or B co-infections | 14 | 6.8 | 3.2 – 13.7 | 13 | 23.2 | 44.0 | 0.8 | 0.039 | 0.0007 |
| Bacterial co-infections\* | 15 | 19.9 | 14.3 – 26.9 | 14 | 21.1 | 33.6 | 0.2 | 0.100 | 0.0095 |
| **Radiological Investigations** | | | | | | | | | |
| *Chest CT* | | | | | | | | | |
| Ground glass opacity | 31 | 35.9 | 29.4 - 43 | 30 | 69.5 | 56.8 | 0.3 | < 0.001 | 0.5934 |
| Consolidation | 26 | 12.3 | 7.0 – 20.7 | 25 | 60.1 | 58.4 | 1.4 | < 0.001 | 0.0187 |
| Patchy shadows | 22 | 26.0 | 16.8 – 37.8 | 21 | 74.3 | 71.7 | 0.9 | <0.001 | 0.4768 |
| Pleural effusion | 16 | 9.3 | 5 – 16.7 | 15 | 18.6 | 19.3 | 0.3 | 0.233 | 0.0141 |
| Unilateral lesion(s) | 19 | 34.8 | 29.9 - 40 | 18 | 18.7 | 3.7 | 0.0 | 0.411 | 0.7729 |
| Bilateral lesion(s) | 17 | 31.3 | 23.3 – 40.7 | 16 | 41.1 | 61.1 | 0.3 | 0.001 | 0.8452 |
| *Chest X-Ray* | | | | | | | | | |
| Consolidation | 6 | 16.7 | 10.8 – 24.9 | 5 | 4.0 | 0.0 | 0.0 | 0.555 | 0.0081 |
| Interstitial infiltrates | 6 | 13.3 | 5.5 - 28.8 | 5 | 9.3 | 46.1 | 0.6 | 0.099 | 0.9116 |

CRP C-reactive Protein, ESR Erythrocyte Sedimentation Rate, IL-6 Interleukin-6, IL-10 Interleukin-10, LFT Liver Function test, LDH Lactate Dehydrogenase, CK Creatinine Kinase, CK-MB, Creatinine Kinase-MB

\* Bacterial– *Mycoplasma pneumoniae*was the causative agent reported in the 15 studies.

**Table 4: Results of meta-analysis: Treatment and outcomes**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Items** | **No. of studies** | **Proportion (%)** | **95% CI** | **n** | **Q** | **I2** | **T2** | **P-value** | **Egger’s test P** |
| **Treatment** | | | | | | | | |  |
| Any treatment | 29 | 93.9 | 87.6 – 97.1 | 28 | 97.3 | 71.2 | 2.7 | < 0.001 | < 0.001 |
| Antiviral | 28 | 82.7 | 62.6 – 93.2 | 27 | 168.8 | 84.0 | 6.4 | < 0.001 | 0.0127 |
| Antibiotic | 26 | 42.9 | 33.3 – 53.1 | 25 | 76.9 | 67.5 | 0.5 | < 0.001 | 0.4711 |
| IVIG | 22 | 11.4 | 4.9 – 24.4 | 21 | 62.7 | 66.5 | 3.1 | < 0.001 | 0.4887 |
| Gluco-corticoids | 19 | 12.6 | 5.6 – 26.0 | 18 | 62.7 | 71.3 | 2.4 | < 0.001 | 0.1052 |
| Hydroxychloroquine | 15 | 5.7 | 2.8 – 11.3 | 14 | 16.2 | 13.5 | 0.3 | 0.302 | 0.5354 |
| **Clinical Course and Outcomes** | | | | | | | | | |
| All hospitalizations | 36 | 95.9 | 91.9 - 98 | 35 | 110.6 | 68.4 | 3.0 | < 0.001 | < 0.001 |
| ICU admissions | 24 | 11.2 | 4.7 – 24.2 | 23 | 105.0 | 78.0 | 3.9 | < 0.001 | 0.3566 |
| Oxygen/NIV\* | 17 | 17.9 | 9.1 – 32.3 | 16 | 54.6 | 70.7 | 1.7 | < 0.001 | 0.9461 |
| Mechanical ventilation | 19 | 7 | 2.9 – 16.1 | 18 | 72.0 | 75.0 | 2.9 | < 0.001 | 0.0116 |
| Shock | 10 | 13 | 3.3 – 39.3 | 9 | 44.1 | 79.6 | 4.1 | < 0.001 | 0.0945 |
| Discharge | 35 | 83.3 | 74.6 – 89.4 | 34 | 113.9 | 70.2 | 1.4 | < 0.001 | 0.2804 |
| Death | 35 | 4.2 | 2.6 – 6.9 | 34 | 44.3 | 23.2 | 0.5 | 0.112 | 0.0155 |

IVIG Intravenous immunoglobulin, ICU Intensive Care Unit, NIV Non-invasive ventilation.